AbbVie Inc. vs Gilead Sciences, Inc. — Stock Comparison
AbbVie Inc. (ABBV) and Gilead Sciences, Inc. (GILD) are both listed on US exchanges. This page compares their Q·Score ratings, key fundamentals (P/E, margins, growth), and Wall Street analyst consensus side by side. Data sourced from Yahoo Finance and updated on each page load.
Gilead Sciences, Inc. clearly outscores AbbVie Inc. on Q·Score (8.2 vs 6 out of 10), led by Quality (9.3 vs 5.8) and Health (7.6 vs 4.3). Analyst price targets imply similar upside for both: +17.2% for ABBV and +17.5% for GILD.
Q·Score Breakdown
75% of 32 covering analysts have a positive rating.
⚠ balance sheet warrants attention.
High-quality business with 43% return on equity and 31% profit margins.
Analyst Consensus
Fundamentals
Frequently Asked Questions
ABBV vs GILD: which stock scores better overall?
Based on Q·Score, Gilead Sciences, Inc. (GILD) scores 8.2/10 versus AbbVie Inc. (ABBV) at 6/10. The Q·Score measures five dimensions: Quality, Health, Growth, Valuation, and Sentiment. For informational purposes only — not financial advice.
Which has better revenue growth: ABBV or GILD?
Gilead Sciences, Inc. (GILD) scores higher on Growth (7.9/10 vs 5.1/10). AbbVie Inc. reports revenue growth (12.4% YoY) while Gilead Sciences, Inc. reports (4.4% YoY). Growth scores reflect revenue and earnings momentum relative to sector peers.
Is ABBV or GILD more attractively valued?
Gilead Sciences, Inc. (GILD) scores higher on Valuation (8.1/10 vs 7.5/10). ABBV trades at 13.3× P/E versus GILD at 14.0×. Valuation is assessed using P/E ratio, analyst price targets, and 52-week range positioning relative to sector peers.
What do analysts say about ABBV vs GILD?
There are 29 analysts covering ABBV with a consensus price target of $252.90, and 29 analysts covering GILD with a consensus target of $157.83. Analyst consensus ratings are aggregated from Wall Street research and do not constitute investment advice.
Which is more profitable: ABBV or GILD?
Gilead Sciences, Inc. (GILD) scores higher on Quality (9.3/10 vs 5.8/10). Net profit margin: ABBV at 5.8%, GILD at 31.0%. Quality scores reflect profit margins, return on equity, and free cash flow generation.
Which has stronger financial health: ABBV or GILD?
Gilead Sciences, Inc. (GILD) scores higher on Financial Health (7.6/10 vs 4.3/10). Market beta: ABBV at 0.30, GILD at 0.33. Health scores consider beta, debt-to-equity, and current ratio. All investments carry risk — this is not investment advice.
What are the market caps of ABBV and GILD?
AbbVie Inc. (ABBV) has a market capitalisation of $381.1B, while Gilead Sciences, Inc. (GILD) has a market cap of $166.8B. Market cap data is sourced from Yahoo Finance and reflects the most recent available figures.
Do ABBV or GILD pay dividends?
ABBV pays a dividend yield of 3.21%, while GILD pays a dividend yield of 2.44%. Dividend yields fluctuate with share price and company payout decisions.
Related Comparisons
Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →